Amarin has lots of cash, no debt, and is earning enough to break even or even to show a profit in the near future...with the the stock price so low, it may be time for Amarin to buy back a sizeable amount of their stock at a tremendous discount.
A buyback would attract attention and might even raise the price enough for a BP to seriously consider a BO.
The roll out of Vascepa in Europe should soon start paying for itself and generating profits....In the meantime, Amarin's cash sitting in the bank doesn't seem to be doing much good for them.
News 
Market Data 
Discover 
AI
